LifeSci Capital analyst Charles Zhu maintained a Buy rating on Nuvalent today and set a price target of $142.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charles Zhu has given his Buy rating due to a combination of factors tied to Nuvalent’s execution and pipeline quality. He highlights the on-time NDA filing for neladalkib in ALK-positive NSCLC, backed by Phase 1/2 ALKOVE-1 data showing compelling response rates and durability across post-lorlatinib, later-line, and first-line settings, with full results still to come at a future medical meeting.
He also points to neladalkib’s Breakthrough Therapy Designation and the potential for priority review, which could accelerate commercialization in a setting where lorlatinib is moving earlier in treatment. In addition, Nuvalent now has two NDAs on file, including zidesamtinib with a 2026 PDUFA date and potential label expansion in first-line ROS1+ NSCLC, all supported by a solid cash runway of roughly three years that should fund ongoing development and key value-inflecting milestones.
In another report released yesterday, Truist Financial also reiterated a Buy rating on the stock with a $140.00 price target.